Free tools Windows power users keep installed
One-click scans. No signup required.
Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Jazz Pharmaceuticals and Vertex Pharmaceuticals are both commercial-stage drug makers, but they offer very different portfolio exposures. Vertex is the much larger company, with $12.0 billion of 2025 revenue, a large cystic-fibrosis franchise and growing contributions from newer medicines. Jazz reported $4.268 billion of 2025 revenue, spread across sleep, epilepsy and oncology products, but it also disclosed substantially more long-term debt. Neither stock is an automatic winner: Vertex generally fits investors prioritizing scale, cash resources and a broader expansion platform, while Jazz may fit investors willing to accept more balance-sheet and product-concentration risk for a smaller, diversified rare-disease business. Your valuation, time horizon, existing holdings and tolerance for drawdowns determine which profile is appropriate.
At a glance
| Name | Best for | Key spec | Checked |
|---|---|---|---|
| Vertex Pharmaceuticals (VRTX) | Investors seeking greater scale, a large established franchise and multiple newer growth platforms | $12.0 billion 2025 revenue; $3.44 billion Q3 2026 revenue, up 12% year over year; $13.15–$13.25 billion 2026 revenue guidance; $9.8 billion cash, cash equivalents and marketable securities at September 30, 2026 | November 2026 |
| Jazz Pharmaceuticals (JAZZ) | Investors seeking a smaller rare-disease portfolio spanning sleep, epilepsy and oncology, and who can accept higher disclosed debt | $4.268 billion 2025 revenue; $1.657 billion 2025 Xywav sales; $1.059 billion 2025 Epidiolex/Epidyolex sales; $2.9 billion cash, cash equivalents and investments and $5.6 billion long-term debt principal at September 30, 2026 | November 2026 |
Prices checked November 2026.
The figures in this table are company-reported results or guidance, not forecasts of shareholder returns. Vertex’s guidance is management’s outlook, and Jazz’s cash and debt figures are point-in-time balances.
As an Amazon Associate I earn from qualifying purchases.
What are Jazz Pharmaceuticals and Vertex Pharmaceuticals?
Jazz Pharmaceuticals is a specialty biopharmaceutical company whose marketed portfolio is concentrated in rare sleep disorders, epilepsy and oncology. Its leading products include Xywav for sleep-related indications and Epidiolex/Epidyolex for certain seizure disorders, with oncology products such as Zepzelca and Rylaze/Enrylaze adding another revenue stream. Jazz also reported launches or approvals for Modeyso and first-line maintenance Zepzelca and described progress for zanidatamab in oncology.
Vertex is a larger biotechnology company historically associated with cystic fibrosis (CF). Its recent commercial expansion includes CASGEVY, a gene-editing therapy, JOURNAVX for pain and PALSONIFY for acromegaly, while its pipeline spans kidney disease, pain, endocrine conditions and other areas. The two companies therefore overlap as commercial drug developers but are not direct substitutes in disease focus, revenue scale or balance-sheet structure.
Popular on Amazon
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
How different are their scale and growth profiles?
Vertex’s reported revenue base is roughly three times Jazz’s on the latest full-year figures. Vertex reported $12.0 billion of total revenue for 2025, while Jazz reported $4.268 billion, including $4.022 billion of net product sales. Scale can support larger research programs, commercial infrastructure and financing options, but it does not by itself predict future stock performance or valuation.
| Measure | Jazz Pharmaceuticals | Vertex Pharmaceuticals | How to read it |
|---|---|---|---|
| 2025 total revenue | $4.268 billion | $12.0 billion | Historical company-reported sales for the year ended December 31, 2025 |
| Latest reported quarter | Third quarter 2026 results and updated full-year guidance | $3.44 billion in Q3 2026 revenue, up 12% year over year | Quarterly momentum is not directly comparable without each company’s full release and accounting context |
| 2026 revenue outlook | Updated full-year guidance was reported, but the supplied evidence does not provide a single comparable figure | $13.15–$13.25 billion management guidance | Guidance is a forecast, not a guarantee |
Vertex’s November 2, 2026 release reported third-quarter revenue of $3.44 billion, a 12% year-over-year increase, and raised its full-year 2026 revenue guidance to $13.15–$13.25 billion. Those figures show continued expansion from a large base, but investors should separate realized quarterly revenue from the forward-looking guidance range.
Jazz’s 2025 sales show a meaningful business, but one with fewer products contributing the majority of revenue. Xywav generated $1.657 billion in net product sales and Epidiolex/Epidyolex generated $1.059 billion in 2025. Together, those two products represented a large share of the company’s net product sales, so product-level changes can have an outsized effect on consolidated results. Jazz’s third-quarter 2026 release should be used for the exact updated guidance range and quarter-specific operating details.
Which company has the more diversified product portfolio?
Jazz has therapeutic diversification across three main areas, but that does not eliminate concentration risk. Sleep products, especially Xywav, are a core earnings engine; Epidiolex/Epidyolex anchors epilepsy; and oncology products provide a third franchise. The portfolio can reduce reliance on one disease area, yet the two largest named products still account for substantial sales, and each faces its own access, competition, patent, safety and execution questions.
Also popular on Amazon
Jazz’s oncology strategy is also in transition. Zepzelca and Rylaze/Enrylaze contribute current sales, while Modeyso and first-line maintenance Zepzelca represent newer commercial activity described in the company’s 2025 and 2026 materials. Zanidatamab is a pipeline and regulatory opportunity rather than an established revenue stream. Rob Iannone, Jazz’s executive vice president and chief medical officer, said: “Jazz had a transformative year across our R&D pipeline, led by the HERIZON-GEA-01 data, which we believe firmly positions zanidatamab as the HER2-targeted agent of choice, with the potential to reshape first-line treatment for HER2+ metastatic GEA patients.” That is management’s characterization of the program, not an independent conclusion about eventual adoption.
Vertex remains heavily tied to CF, a franchise that has generated the company’s scale and commercial cash flow. Its diversification effort is further along in revenue terms than a purely pre-commercial pipeline: the company reported third-quarter 2026 revenue of $99 million for CASGEVY and $58 million for JOURNAVX, and said PALSONIFY was approved in the United States for acromegaly after inadequate response to surgery or when surgery is not an option. These contributions are still small relative to the CF base, so investors should ask whether the new products can become material businesses rather than assuming that approval equals financial diversification.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Vertex chief executive Reshma Kewalramani described 2025 as a year of “strong revenue growth, commercial diversification, and pipeline advancement.” In its third-quarter update she said Vertex delivered “strong revenue growth across the increasingly diversified portfolio” and completed the Crinetics Pharmaceuticals acquisition. Those statements reflect management’s view; long-term product uptake, pricing, reimbursement and profitability remain uncertain.
What do the latest balance-sheet figures show?
The companies report different combinations of cash, investments and debt, so the figures should not be reduced to a simplistic “strong” or “weak” label. Jazz reported $2.9 billion in cash, cash equivalents and investments and $5.6 billion in long-term debt principal as of September 30, 2026. Vertex reported $9.8 billion in cash, cash equivalents and marketable securities on the same date.
Also popular on Amazon
| Balance-sheet item | Jazz | Vertex | Important qualification |
|---|---|---|---|
| Cash, cash equivalents and investments (September 30, 2026) | $2.9 billion | — | Jazz figure is from its Q3 2026 release; do not treat it as net cash |
| Cash, cash equivalents and marketable securities (September 30, 2026) | — | $9.8 billion | Vertex said the balance declined from year-end partly because of the Crinetics acquisition and share repurchases |
| Long-term debt principal (September 30, 2026) | $5.6 billion | — | Jazz’s principal amount is not the same as an income-statement interest expense |
| Other financing disclosed | Acquisition-related obligations and debt are key analytical questions | $4.5 billion term loan, alongside acquisition spending and operating cash flows | Terms, maturities, covenants and cash generation require review of the filings |
Jazz’s debt principal exceeds its reported cash, cash equivalents and investments, but that comparison alone does not establish debt sustainability. An investor would need maturities, interest rates, free cash flow, covenant details, refinancing options and the value of ongoing products before judging leverage. The larger debt load can make Jazz’s equity more sensitive to product setbacks or higher financing costs, while acquisitions may create opportunities as well as obligations.
Vertex’s larger cash balance provides more visible financial resources, but it should be read with capital allocation decisions. The company said cash declined from year-end partly because of the Crinetics acquisition and share repurchases, offset in part by a $4.5 billion term loan and operating cash flow. Cash is therefore not idle money: acquisitions, debt service, research spending and buybacks all affect how much remains available for future investment.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →What pipeline and regulatory catalysts should investors watch?
For Jazz, the central questions are whether newer oncology products can scale, whether zanidatamab can convert encouraging clinical and regulatory progress into a durable franchise, and whether epilepsy and oncology growth can offset product-specific headwinds in sleep medicines. Modeyso and the first-line maintenance use of Zepzelca are commercial developments, while zanidatamab remains dependent on regulatory review, launch execution, physician adoption and reimbursement. Investors should track indication-specific approvals and sales rather than treating every pipeline announcement as a near-term earnings driver.
For Vertex, the most visible near-term regulatory milestone in the supplied evidence is povetacicept for IgA nephropathy. Vertex said the application was under priority review with an FDA target action date of November 30, 2026. A target action date is an agency timetable, not an approval, label, launch date or revenue forecast. The potential nephrology franchise could broaden Vertex beyond CF, but clinical evidence, regulatory conditions, manufacturing, payer coverage and uptake all remain uncertain.
Also popular on Amazon
Vertex’s pipeline also includes programs in pain, kidney diseases, endocrine conditions and other areas. CASGEVY, JOURNAVX and PALSONIFY provide commercial proof that the company is adding products, but their reported quarterly revenue remains much smaller than the established CF business. The investment question is not simply how many programs exist; it is whether they can reach meaningful scale while the core franchise remains durable.
What are the main risks for a Jazz investment?
- Product concentration: Xywav and Epidiolex/Epidyolex generated $1.657 billion and $1.059 billion, respectively, in 2025 net product sales. A change in demand, reimbursement, competition, safety perception or intellectual-property protection for either product could affect company results disproportionately.
- Debt and financing flexibility: The $5.6 billion of long-term debt principal reported at September 30, 2026 must be serviced alongside research, launch and acquisition spending. Review maturities and cash-flow coverage rather than relying on the principal figure alone.
- Pipeline execution: New oncology products and zanidatamab could expand the portfolio, but clinical, regulatory and commercial outcomes are uncertain. Management’s positive descriptions are not guarantees.
- Rare-disease access and pricing: Specialty medicines often depend on diagnosis, specialist prescribing, payer authorization and support services. Delays or restrictions in any of these channels can slow sales even when a therapy is approved.
What are the main risks for a Vertex investment?
- CF concentration: Vertex’s scale is still closely linked to cystic fibrosis. A large established franchise can be an advantage, but dependence on one therapeutic area leaves the company exposed to market, pricing, competitive and scientific changes in that area.
- Expansion risk: CASGEVY, JOURNAVX, PALSONIFY and potential kidney products must be developed, manufactured, reimbursed and commercialized. New-product revenue does not automatically translate into durable earnings or returns.
- Regulatory uncertainty: The November 30, 2026 target action date for povetacicept may result in approval, a delay, a request for more information or another outcome. Investors should not price a pending decision as certain.
- Capital-allocation and integration risk: The Crinetics acquisition, a $4.5 billion term loan and share repurchases change the company’s capital structure and cash uses. Integration and future returns on acquired assets will determine whether those decisions create value.
Can you tell which stock is cheaper?
Not from the supplied evidence. A proper valuation comparison requires dated share prices, shares outstanding, market capitalization, enterprise value, earnings or cash-flow measures and the calculation date. None of those current market inputs was established here, so assigning a “cheaper” or “better value” verdict would be guesswork.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsRevenue scale is not a valuation multiple, and a higher revenue-growth rate is not automatically a higher expected shareholder return. Before buying either stock, use a current market source and the latest filings to calculate the measures that match your strategy: price-to-earnings for mature profitability, enterprise value to operating cash flow where appropriate, free-cash-flow yield, and scenario-based estimates for pipeline products. Keep the date fixed across both companies; comparing a current price for one with an older filing for the other can produce a misleading result.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Which stock fits a conservative, growth-oriented or diversified portfolio?
Portfolio fit depends on the role you want the position to play, not on a universal ranking.
Also popular on Amazon
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
| If your priority is… | Profile that may fit better | What you must accept or verify |
|---|---|---|
| Scale and a larger cash resource | Vertex | CF remains a major earnings base; newer products and pipeline programs must prove durable adoption |
| Exposure to several rare-disease categories in a smaller company | Jazz | Higher disclosed debt and greater sensitivity to a few key products |
| A nearer-term diversification story beyond CF | Vertex, if you believe CASGEVY, JOURNAVX, PALSONIFY and kidney programs can scale | Current new-product revenue is modest relative to the CF franchise, and regulatory and commercial outcomes are uncertain |
| Potential operating leverage from newer oncology assets | Jazz, if zanidatamab and newer products execute | Pipeline and launch outcomes are not guaranteed, and debt can magnify downside |
| Lower single-company exposure | Neither as a standalone solution | A diversified healthcare fund or a position sized alongside other sectors may reduce company-specific risk |
An investor already holding a large biotechnology position may view Jazz and Vertex differently from someone starting with no healthcare exposure. Check how much of your portfolio is already linked to prescription-drug pricing, regulatory decisions, rare diseases or large-cap growth. Position size can matter as much as the choice between these two names.
How should you compare Jazz and Vertex before buying?
- Set the decision date. Record the share price, market capitalization and exchange data on the same day for both companies. The research summarized here is current through November 13, 2026, but it does not supply market valuations.
- Separate reported facts from forecasts. Put 2025 revenue and third-quarter 2026 revenue in one column, and management guidance, trial expectations and regulatory target dates in another.
- Map revenue by product. For Jazz, start with Xywav, Epidiolex/Epidyolex, Zepzelca and Rylaze/Enrylaze. For Vertex, separate CF from CASGEVY, JOURNAVX, PALSONIFY and any potential kidney franchise.
- Read the debt footnotes. Review maturities, interest rates, covenants, refinancing needs and acquisition obligations. Cash balances without those details cannot show how resilient a company is in a downturn.
- Build approval and launch scenarios. Treat povetacicept’s November 30, 2026 date as a milestone to monitor, not a guaranteed approval. Apply the same discipline to zanidatamab and Jazz’s newer oncology products.
- Stress-test concentration. Ask what happens if the largest product grows slowly, faces a competitor, loses reimbursement or encounters a safety issue. Compare that downside with your acceptable portfolio drawdown.
- Check the latest filings after any catalyst. An approval, label change, acquisition or guidance revision can alter revenue timing, expenses, debt and valuation. Update the comparison rather than relying on this snapshot.
What is the practical conclusion for a portfolio decision?
Vertex is the clearer fit for an investor who values a larger revenue base, substantial reported cash resources and an expansion strategy that is already producing revenue outside CF. Jazz is the more targeted fit for an investor who wants exposure to sleep, epilepsy and oncology through a smaller commercial company and is prepared to analyze higher disclosed debt and concentration in a few products.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →That distinction is a framework, not a recommendation. The right choice can reverse if valuation differs materially, a product outlook changes, debt is refinanced, or a regulatory decision changes the pipeline. Use the latest company releases and SEC filings, combine them with current market data, and size either position according to the risks your existing portfolio can absorb.
Frequently Asked Questions
Are Jazz Pharmaceuticals and Vertex Pharmaceuticals profitable?
The supplied materials establish revenue, product sales, cash and debt, but they do not provide a like-for-like profitability comparison. Use each company’s latest income statement and cash-flow statement to compare operating margin, net income, diluted earnings per share and free cash flow on the same reporting basis.
How could an FDA decision affect Vertex shareholders?
A decision on povetacicept could change expectations for Vertex’s potential kidney-disease franchise, but the effect would depend on the label, launch timing, clinical data and market size. The November 30, 2026 target action date is an agency timetable, not a promised approval or a guaranteed stock reaction.
What should Jazz investors monitor besides Xywav sales?
Track Epidiolex/Epidyolex trends, oncology launches such as Modeyso and first-line maintenance Zepzelca, zanidatamab milestones, and debt maturities. Reimbursement changes, new competitors and the pace at which newer products replace or supplement established sales can matter as much as quarterly revenue.
Can owning both stocks diversify a healthcare portfolio?
Owning both gives exposure to two companies with different portfolios, but both remain exposed to biotechnology-specific risks such as regulation, reimbursement, clinical evidence and drug pricing. Holding both does not replace diversification across sectors, geographies and asset classes, and their shared industry risks can still produce correlated declines.
